Show simple item record

dc.contributor.authorBaird, R
dc.contributor.authorGarcia-Corbacho, J
dc.contributor.authorRamenatte, N
dc.contributor.authorJonson, A
dc.contributor.authorAhmad, S
dc.contributor.authorSmith, D
dc.contributor.authorQian, W
dc.contributor.authorKumar, S
dc.contributor.authorLinossi, C
dc.contributor.authorMatys, T
dc.contributor.authorGraves, M
dc.contributor.authorJodrell, D
dc.contributor.authorCaldas, C
dc.contributor.authorPacey, S
dc.contributor.authorWhitfield, Gillian A
dc.contributor.authorChalmers, A
dc.contributor.authorJena, R
dc.contributor.authorPrice, S
dc.contributor.authorJefferies, S
dc.contributor.authorWatts, C
dc.date.accessioned2017-05-01T20:26:51Z
dc.date.available2017-05-01T20:26:51Z
dc.date.issued2016-10-01
dc.identifier.citationCamBMT1: A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases (mets) for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy. 2016, 27 (suppl 6):408TiP Annals of Oncologyen
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.doi10.1093/annonc/mdw368.51
dc.identifier.urihttp://hdl.handle.net/10541/620302
dc.language.isoenen
dc.relation.urlhttps://academic.oup.com/annonc/article/2799147/CamBMT1:en
dc.rightsArchived with thanks to Annals of Oncologyen
dc.titleCamBMT1: A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases (mets) for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentBreast Cancer Research Unit, Addenbrookes Hospital Box 97, Cambridge Cancer Centre, Cambridgeen
dc.identifier.journalAnnals of Oncologyen


This item appears in the following Collection(s)

Show simple item record